{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:05:07Z","timestamp":1775228707727,"version":"3.50.1"},"reference-count":0,"publisher":"Therapeutic Guidelines Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aust Prescr"],"DOI":"10.18773\/austprescr.2022.071","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T20:24:53Z","timestamp":1665519893000},"page":"213","source":"Crossref","is-referenced-by-count":0,"title":["New drug: Decitabine\/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes"],"prefix":"10.18773","volume":"45","member":"39051","published-online":{"date-parts":[[2022,10,12]]},"container-title":["Australian Prescriber"],"original-title":[],"link":[{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/decitabine-cedazuridine-for-chronic-myelomonocytic-leukaemia-myelodysplastic-syndromes.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:18:42Z","timestamp":1775225922000},"score":1,"resource":{"primary":{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/decitabine-cedazuridine-for-chronic-myelomonocytic-leukaemia-myelodysplastic-syndromes.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,11,30]]}},"URL":"https:\/\/doi.org\/10.18773\/austprescr.2022.071","relation":{},"ISSN":["1839-3942"],"issn-type":[{"value":"1839-3942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}